| Literature DB >> 26793696 |
Abstract
Generalized edema is a major presenting clinical feature of children with nephrotic syndrome (NS) exemplified by such primary conditions as minimal change disease (MCD). In these children with classical NS and marked proteinuria and hypoalbuminemia, the ensuing tendency to hypovolemia triggers compensatory physiological mechanisms, which enhance renal sodium (Na(+)) and water retention; this is known as the "underfill hypothesis." Edema can also occur in secondary forms of NS and several other glomerulonephritides, in which the degree of proteinuria and hypoalbuminemia, are variable. In contrast to MCD, in these latter conditions, the predominant mechanism of edema formation is "primary" or "pathophysiological," Na(+) and water retention; this is known as the "overfill hypothesis." A major clinical challenge in children with these disorders is to distinguish the predominant mechanism of edema formation, identify other potential contributing factors, and prevent the deleterious effects of diuretic regimens in those with unsuspected reduced effective circulatory volume (i.e., underfill). This article reviews the Starling forces that become altered in NS so as to tip the balance of fluid movement in favor of edema formation. An understanding of these pathomechanisms then serves to formulate a more rational approach to prevention, evaluation, and management of such edema.Entities:
Keywords: children/pediatrics; edema; management; nephrotic syndrome; pathophysiology
Year: 2016 PMID: 26793696 PMCID: PMC4707228 DOI: 10.3389/fped.2015.00111
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Pathophysiology of edema formation in NS. In disorders with massive proteinuria and marked hypoalbuminemia but minimal or absent renal inflammatory infiltrate, as in most children with minimal-change disease (MCD), the reduction in capillary colloid oncotic pressure (πcap) favors net fluid exit from the vascular to the interstitial fluid compartment thereby reducing effective circulatory blood volume, denoted as “underfill.” This then triggers secondary, or compensatory, Na+ retention and hemodynamic alterations aimed at achieving blood pressure homeostasis. By contrast, various glomerulonephritides and inflammatory renal disorders, such as acute post-streptococcal glomerulonephritis, may be associated with variable degrees of proteinuria and with pathologic release of mediators, which promote primary renal Na+ and water retention, as well as vasoconstrictive hormones that are released despite an intact or even expanded intravascular volume. These factors together with reduction in glomerular ultrafiltration coefficient (Kf, or LpS in the Starling equation), lead to reduced glomerular filtration rate (GFR) and combine to further limit Na+ excretion, resulting in an “overfill” state and rise in capillary hydraulic pressure (Pcap). In turn, this causes net fluid accumulation in the interstitial fluid compartment. Note that nephrotic urine may be a common pathway for primary Na+ retention in both undefill and overfill disorders (refer to text and Tables 1–3 for the mediators sub-serving each of these main mechanisms of edema formation).
Contribution of volume and blood pressure regulatory hormones and channels which mediate or participate in renal Na.
| Hormones and channels | Function |
|---|---|
| RAAS activation | Direct stimulation of active Na+ reabsorption in the PCT by AT II; aldosterone-mediated Na+ retention |
| Non-osmotic ADH/vasopressin release | Water retention in CD, vasoconstriction |
| Norepinephrine (NE) release | α-Adrenergic stimulation of renal tubular Na+ reabsorption; vasoconstriction |
| Atrial natriuretic peptide (ANP) release | Promotes natriuresis and diuresis in DCT and CD, but tubular epithelium is resistant to these effects in NS |
| Urodilatin activation | Promotes natriuresis and diuresis in DCT and CD, but tubular epithelium is resistant to these effects in NS |
| Phosphodiesterase activation | Promotes degradation of ANP and urodilatin |
| Sodium-hydrogen exchanger 3 (NHE3) activation | Mediates Na+ reabsorption in PCT |
| Epithelial sodium channel (ENaC) activation by plasmin loss in nephrotic urine | Stimulates Na+ reabsorption in the DCT and CD |
| Sodium potassium ATPase (Na+/K+ ATPase) activation | Provides energy for pumps involved in active Na+ transport and facilitates peritubular uptake of Na+ by exporting Na+ out of cells in the anti-lumenal side of CCT |
RAAS, renin angiotensin aldosterone system; AT II, angiotensin II; Na.
Mechanism of edema formation in nephrotic syndrome: “overfilling”.
| Normal or elevated BP without tachycardia or orthostatic symptoms, and no signs to indicate distal extremity hypoperfusion |
| FENa+ > 0.5% while on no salt restricted diet |
| UK+/UK+ + UNa+ < 60% (decreased TTKG index) |
| Hematuria and cellular casts |
| Serum albumin >2 g/dL |
| Elevated serum creatinine and BUN |
| GFR < 50 mL/min/1.73 m2 |
| Decreased vasopressin |
| Low circulating PRA and norepinephrine |
| Low or normal plasma aldosterone |
| High ANP |
FE.
Mechanism of edema formation in nephrotic syndrome: “underfilling”.
| Neuromuscular weakness, pallor, cool extremities, tachycardia, and other signs and symptoms of orthostatic hypotension, abdominal pain secondary to gut edema, abdominal compartment syndrome, or thrombosis of vena cave or renal veins |
| Reduced urine volume |
| FENa+ < 0.2% |
| UK+/UK+ + Na+ > 60% (increased TTKG index) |
| Reduced urinary Na+ and high potassium concentration |
| Very low serum albumin (≤2 g/dL) |
| Low serum creatinine level |
| GFR > 75 mL/min/1.73 m2 |
| Hemoconcentration |
| High circulating PRA, aldosterone, vasopressin, and norepinephrine |
| Low ANP concentration |
FE.
General aspects of management of edema in children with NS.
| Avoid placement of deep lines to prevent thromboembolic events |
| Reduce dietary salt |
| No fluid restriction unless brisk diuresis is achieved |
| Insure adequate nutrition |
| Monitor urine output, renal function, electrolytes, serum albumin, body weight, and vital signs |
| Elevate extremities or use compression stockings when ambulating; water immersion is helpful but impractical |
| Avoid ACE inhibitors as remission can occur in many children with corticosteroid monotherapy |
Albumin infusion in the management of edema in NS.
| 0.5 g/kg infused over 1-h, 2–3 times daily. Slower infusion rates may enhance equilibration of albumin between the intravascular and interstitial fluid compartments, thereby undermining fluid mobilization and removal. Larger dosages may be more effective but may cause acute volume expansion and pulmonary congestion |
| Tense ascites with abdominal compartment syndrome limiting diaphragmatic excursion, lymphatic flow, and venous return |
| Severe pleural effusions compromising breathing |
| Oliguria with incipient acute kidney injury (AKI) |
| Marked eyelid edema compromising vision |
| Severe scrotal or labial edema, risking skin breakdown |
| Expensive |
| Low supply |
| Obtained from multiple blood donors risking viral transmission, tissue allosensitization, etc. |
| Pulmonary edema |
Diuretics used to manage edema in children.
| Diuretic class, name, mechanism, and site of action | Bioavailability % PO/IV ratio | Onset of action (min) PO/IV | Duration of action (h) | Dosing | |
|---|---|---|---|---|---|
| Furosemide | 60 | 1.5 | 40/5 | 6 | Neonates: p.o. 1–4 mg/kg/dose, 1–2×/day iv/im 1–2 mg/kg/dose q 12–24 h |
| Bumetanide | 85 | 1 | 40/5 | 4 | Children: p.o./iv/im 1–2 mg/kg/dose q 6–12 h |
| Torsemide, ethacrynic acid | <6 months: p.o./iv/im 0.05–0.05 mg q 24 h | ||||
| Inhibit the Na+/K+/2Cl− cotransport system in the thick ascending limb of Henle’s loop (ALH) | >6 months: p.o./iv/im 0.015 mg/kg q 24 h; max. 0.1 mg/kg/dose | ||||
| Chlorothiazide | 11–20 | 120 | 24 | <6 months: p.o. 20–40 mg/kg/day divided bid iv 2–8 mg/kg/day divided bid | |
| Hydrochlorothiazide | 60–75 | 120 | 12–24 | >6 months: p.o. 20 mg/kg/day divided bid iv 4 mg/kg/day | |
| Inhibit NaCl cotransport in the early distal convoluted tubule (DCT) | <6 months: p.o. 2–3.3 mg/kg/dose divided bid | ||||
| Metolazone | 40–60 | 60 | 24 | Children: 0.2–0.4 mg/kg/day divided q 12–24 h | |
| Similar to thiazides but also proximal tubular inhibition of sodium uptake | |||||